Kestra Medical director Kevin Reilly sells $73,677 in shares By Investing.com

Kevin C. Reilly, a director at Kestra Medical Technologies, Ltd. (), recently sold common shares totaling $73,677. The transaction occurred on September 8, 2026, involving 2,932 shares.

The shares were sold at a weighted average price of $25.1287, with individual sales prices ranging from $24.9100 to $25.3500. This sale was a nondiscretionary transaction, required to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. Following this sale, Mr. Reilly directly held 5,368 common shares.The transaction comes as Kestra Medical’s stock has declined, currently trading at $23.57, down from the $25.13 average sale price. According to InvestingPro analysis, the stock appears overvalued at current levels. The company reports earnings on September 14, just days away. Investors seeking deeper insights can access comprehensive analysis through the Pro Research Report, available for KMTS and 1,400+ other US equities.

Separately, on September 9, 2026, Mr. Reilly was granted 7,217 restricted stock units. Each unit entitles him to receive one common share of Kestra Medical Technologies, Ltd. These restricted stock units are scheduled to vest on September 9, 2027, contingent upon Mr. Reilly’s continued service to the company through that date. After these transactions, Mr. Reilly directly beneficially owned a total of 12,585 common shares, including the restricted stock units.

In other recent news, Kestra Medical Technologies reported a significant rise in revenue for its fiscal fourth quarter of 2026, with total revenue reaching $28.6 million, marking a 66% increase year-over-year. Despite this impressive growth, the company missed Wall Street’s earnings expectations, posting an earnings per share loss of $0.67, compared to the forecasted loss of $0.58. Stifel reiterated a Buy rating for Kestra Medical, emphasizing the strong growth and setting a price target of $30.00. Wolfe Research also raised its price target for Kestra Medical to $30.00, maintaining an Outperform rating due to the company’s execution exceeding expectations. JPMorgan initiated coverage with an Overweight rating, highlighting the potential of Kestra’s ASSURE wearable cardioverter defibrillator. Oppenheimer initiated coverage with a Perform rating, pointing to the large addressable market and Kestra’s ongoing market share gains. These developments reflect Kestra Medical’s strong performance and growing presence in the wearable medical device market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.